JOURNAL Allergy, Asthma & Clinical Immunology
Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action READ MORE…STUDY
Depression is on the rise around the world and, according to one author, the World Health Organization (WHO) has stated that approximately 300 million people worldwide suffer from this debilitating disorder
Author, Amy Morin, LCSW, wrote in her article, Depression Statistics Everyone Should Know, that in the United States alone, 16.2 million adults have experienced a major depressive episode in the past year.
Dr.Kelly Brogan’s paper outlined the strong possibility that the aluminum adjuvant that is currently being used in at least 18 childhood vaccinations may be responsible for the increase in long-term brain inflammation, neurological complications and autoimmunity. She stated that:
“One of the most relevant aluminum-containing vaccines is Gardasil, responsible for more than 34000 reported adverse events,and now Gardasil 9, which contains twice the aluminum dose (ie, now with 500 μg per 3 recommended doses).”
EXCERPT ON ALUMINUM
Either by oral ingestion as salt or as an adjuvant, Al exposure may
induce the dysfunction or activation of glial cells that are important in
maintaining the homeostasis of the CNS and in neurodevelopment
(Morris et al., 2017). Furthermore, Al can induce the activation of
microglia to produce TNF-α, IL-6, iNOS, NOS-2, neuroinflammatory
PICs and ROS (Zaky et al., 2013). The microglia may govern the regulation
of neurogenesis and neurodevelopmental factors and interfere
with synaptic pruning and with the proliferation of neurons, which in
turn, may lead to the development of ASD (Kettenmann et al., 2013;
Edmonson et al., 2016; Hoeijmakers et al., 2016).
In February 2018, the FDA and CDC approved the recommendation for a new hepatitis B vaccine, Heplisav-B targeting adults over the age of 18. The U.S. Food and Drug Administration (FDA) had twice rejected the application for licensure for Heplisav-B in the past four years because of safety signals. Heplisav-B differs from other licensed hepatitis B vaccines in that it contains a new synthetic adjuvant known as cytosine phosphoguanine 1018 (CpG 1018) composed of short synthetic DNA molecules. In 2016, the FDA rejected an application for licensure for the Heplisav-B vaccine, because the agency was concerned about an increased rate of heart attacks and deaths in people who had been given the vaccine. During the trial, approximately 14 subjects had heart attacks. In July 2017, the FDA committee convened to re-evaluate the scientific evidence and make a decision on whether Heplisav B should or should not be approved for use in the U.S. This committee had only one cardiologist on the team, Milton Packer, MD, who is a distinguished scholar in cardiovascular science at the Baylor University Medical Center in Dallas, Texas. According to Dr. Packer, it was possible that the Heplisav B vaccine’s novel adjuvant was related to the higher number of heart attacks in study participants who received the experimental vaccine. He stated: “To know if the 7 -1 heart attack imbalance represented a real risk, we’d need comparative data in 50,000 people.” However, the only way to conduct such a large trial would be to approve the vaccine and see what happens in the public. With Dr. Packer abstaining in his vote to recommend the vaccine, the FDA committee approved it anyway. Dr. Packer stated: “Why did I abstain? Based on the available data, it was impossible for anyone to know if the increase in heart attack risk was real. There is a simple rule in life: if you don’t know, you should say you don’t know.” The vaccine is now available to the public, and all those who receive it are basically guinea pigs to find out if heart attacks will result from the experimental vaccine, and if it will continue to have FDA approval.
Study on combining Aluminum with 1018 (CPG1018 as above)
Abstract. There are unexplained links between human exposure to aluminium and the incidence, progression and aetiology of Alzheimer’s disease. The null hypothesis which underlies any link is that there would be no Alzheimer’s disease in the effective absence of a body burden of aluminium. To test this the latter would have to be reduced to and retained at a level that was commensurate with an Alzheimer’s disease-free population. In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium. This same mechanism might now be applied to both the removal of aluminium from the body and the reduced entry of aluminium into the body while ensuring that essential metals, such as iron, are unaffected. Based upon the premisethat urinary aluminium is the best non-invasive estimate of body burden of aluminium patients with Alzheimer’s disease were asked to drink 1.5 L of a silicic acid-rich mineral water each day for five days and, by comparison of their urinary excretion of aluminium pre-and post this simple procedure, the influence upon their body burden of aluminium was determined. Drinking the mineral water increased significantly (P <0.001) their urinary excretion of silicic acid (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol
creatinine) and concomitantly reduced significantly (P = 0.037) their urinary excretion of aluminium (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). The latter was achieved without any significant (P >0.05) influence upon the urinary excretion of iron (20.7 ± 9.5 to 21.7 ± 13.8 nmol/mmol creatinine). The reduction in urinary aluminium supported the future longer-term
use of silicic acid as non-invasive therapy for reducing the body burden of aluminium in Alzheimer’s disease.
FDA regulations require safety testing of constituent ingredients in drugs (21 CFR 610.15). With the exception of extraneous proteins, no component safety testing is required for vaccines or vaccine schedules. The dosing of aluminum in vaccines is based on the production of antibody titers, not safety science. Here we estimate a Pediatric Dose Limit that considers body weight. We identify several serious historical missteps in past analyses of provisional safe levels of aluminum in vaccines, and provide updates relevant to infant aluminum exposure in the pediatric schedule considering pediatric body weight
VLA comment: Apparently it is okay with the CDC and Paul Offit at the Philadelphia Children’s Hospital that…and I quote and excerpt…the process which a small infant has to deal with excreting this poison or the consequences of retain the metal in the bones or the brains is inconsequental:
“We investigated hepatic P450 metabolism and drug pharmacokinetics in type 1 allergic mice induced by ovalbumin (OVA) emulsified with aluminum and inactive Bordetella pertussis. To further propose a possible key factor in drug-allergic disease interactions, we examined the inhibitory effect of NO, a marker of allergic conditions on the activities of major P450 isoforms”.